Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia.

Background/aim: Atrophic gastritis (AG) is the most important risk condition for gastric cancer (GC). A panel of stomach-specific serum biomarkers: pepsinogen (PG) I, pepsinogen (PG) II, gastrin-17 (G-17), and IgG antibodies to H. pylori (HP-Ab) detects the extent and grade of AG.

[Pancreatic cancer (data of the Registry in Novosibirsk, risk factors, prevention options)].

Dynamics of morbidity and mortality from pancreatic cancer in the population of Novosibirsk according to the Population-based Cancer Registry and the Registry of total mortality for 25 years (1988-2012) were analyzed. The morbidity and mortality for the studied period decreased slightly. Incidence rates in middle-aged males are higher than in females but this difference is leveled after 75 years.

[25-year trends of incidence and mortality from liver cancer and viral hepatitis in Novosibirsk].

The article presents data of Cancer Registry in Novosibirsk for the period 1988-2012 concerning primary liver cancer. Over the period studied the incidence and mortality have declined significantly (2,5 and 2,1 times, respectively). Both figures fall in line for men and women being generally twice as high in men.

[Risk of gastric cancer dependent on serological markers of atrophic gastritis: cohort study].

In a prospective study the risk of subsequent gastric cancer (GC) was assessed in persons aged 45-69 over 5 years after the initial testing with a set of serological tests (pepsinogen I, pepsinogen II, gastrin-17, antibodies to Helicobacter pylori). The presence of gastric atrophy markers was a significant predictor of GC in the forthcoming years. Non-invasive techniques may be used in the formation of high-risk groups, followed by GC active surveillance.